Trump Claims Credit for the Steepest Drug Price Drop Since 1963 - But Experts Aren't So Sure

If lower prescription drug costs will help you lower your financial stress, some genuinely good news arrived in August: Federal data shows prescription drug prices posted their steepest annual decline in more than six decades. While the drop is real, the question of who or what caused it is more complicated, and the debate over the answer has political stakes with the November midterms approaching.

Here is what the data says, what the White House is claiming, what drug-pricing experts are saying instead, and why many patients may not feel the difference in their own wallets.

What the data actually shows

The Bureau of Labor Statistics' Consumer Price Index report released August 12 found that prescription drug prices fell 0.8% from June to July 2026 on a seasonally adjusted basis and dropped 3.1% over the 12 months ending in July, the steepest year-over-year decline since March 1963.

The report also found:

• Drug prices have not risen in a single month in 2026 and have fallen in five of the last six months.
• The broader medicinal drugs index (which includes over-the-counter medications) fell 2.7% over the year, reportedly the largest such drop on record.
• Over the same period, hospital services rose 5.2%, and physicians' services rose 2.4%.

While the decline is real, the CPI index tracks what pharmacies are paid by insurers and consumers on a transaction basis, not list prices and not individual out-of-pocket costs. More on why that matters below.

The administration's position

The White House moved quickly to claim the data as a political win. "From his Most-Favored-Nations deals to launching TrumpRx, President Trump is delivering real results," White House spokesman Kush Desai posted on X after the report was released. "American patients are winning."

The administration points to three specific initiatives:

• Most-Favored-Nation pricing deals: The Trump administration negotiated agreements with 26 pharmaceutical manufacturers requiring them to sell drugs at prices comparable to what they charge in other wealthy countries. These 26 drugmakers are also exempt from new pharmaceutical tariffs through January 2029, providing additional incentive to participate.
• TrumpRx: A White House price-comparison website that connects patients with discounted cash prices for certain drugs. The administration credits it with expanding price transparency and giving patients leverage.
• Medicare GLP-1 Bridge program: Launched in July 2026, this program allows eligible Medicare beneficiaries to obtain weight-loss drugs including Wegovy, Zepbound, and Foundayo at a net monthly price of $245 with a $50 copay, substantially below retail prices that can run into the thousands of dollars monthly.

What the experts say

Drug-pricing analysts largely agree the decline is significant but say the administration's signature policies probably were not the primary drivers.

Richard Frank, a senior fellow at the Brookings Institution and professor emeritus of health economics at Harvard, told The Washington Post that the Biden-era introduction of Medicare price negotiations was more likely the primary cause. "If I was a betting guy on what mattered most, it would be probably stuff around the Inflation Reduction Act," Frank said.

The IRA context: Congress enacted Medicare's authority to negotiate directly with drug manufacturers in the 2022 Inflation Reduction Act. The first negotiated prices on 10 top-selling drugs took effect January 1, 2026. A second round covering 15 more drugs, including Ozempic and Wegovy, is set to take effect in 2027.

Other factors analysts cite alongside or above the administration's specific policies:

• Generic and biosimilar competition continues to erode prices on drugs whose patents have expired.
• The introduction of GLP-1 weight-loss competitors drove price pressure across that whole drug class.
• Changes in the mix of drugs being purchased shifted the overall average.
• Most-Favored-Nation deals with manufacturers are recent, and many had not yet taken full effect at the time the CPI measured the decline, making their contribution to the July figures hard to confirm.

Axios reported that TrumpRx likely accounts for part of the decline but is probably not the dominant factor, while also crediting the Eli Lilly and Novo Nordisk deals on GLP-1 drugs as more directly measurable.

No published analysis has quantified how much each factor contributed. The question of credit remains genuinely contested.

The crucial caveat: What the index does not measure

Even accepting the 3.1% figure as accurate, there is an important gap between that number and what most patients experience.

The BLS CPI measures transaction prices, meaning what pharmacies are paid by insurers and consumers on sampled purchases. It does not measure list prices, manufacturer rebates, or individual out-of-pocket costs at the pharmacy counter. Those figures move independently and are frequently confused in coverage of drug prices.

Practically speaking, many insured patients pay fixed copays that do not change when transaction prices fall. Patients without insurance, or those in the coverage gap on certain plans, may or may not see the decline reflected in what they actually pay.

Over the same 12 months that drug prices fell 3.1%, hospital services rose 5.2%, and physicians' services rose 2.4%. Total health care costs for most American families are not declining. The drug price drop is a genuine bright spot within a broader picture of rising health expenses.

A headwind already building

There is also a forward-looking concern that the current trend may reverse. Vizient's Spend Management Outlook projects pharmaceutical prices will rise 3.54% in 2027, up 0.7 percentage points from its earlier forecast, and that projection does not yet fully account for new pharmaceutical tariffs.

A 100% tariff on patented drugs and their ingredients from large manufacturers took effect July 31 following a Section 232 national security finding. Generic drugs face a separate escalating tariff schedule beginning August 1. The manufacturers with most-favored-nation deals are exempt through January 2029, but the broader industry is not.

The bottom line

The 3.1% drop in prescription drug prices is the largest since 1963, but how much patients save will depend on their medications, insurance coverage, and out-of-pocket costs.

If you want to transform your savings on health care, watch whether drug prices continue falling and whether insurers pass those savings along through lower copays and premiums.

You May Also Like

23 Ways To Get Money Without Getting A Second Job

By FinanceBuzz Editors

How To Save Money on Car Insurance: 12 Ways to Lower Rates

By Elyssa Kirkham

10 Things Seniors Born Between 1941-1969 Could Take Advantage Of

By FinanceBuzz Editors

19 Dumbest Things Smart People Waste Money On

By Team FBZ

7 Moves If You Want to Stop Living Paycheck to Paycheck

By FinanceBuzz Editors

7 Clever Ways to Crush Your Debt

By FinanceBuzz Editors

Up To 5% Cash Back

Discover it^® Cash Back

Benefits Card Details

• Intro APR on purchases and balance transfers
• $0 annual fee
• Apply Now

• Get a 0% intro APR for 15 months on purchases and balance transfers; balance transfer fee applies. Then 17.49% to 26.49% Standard Variable Purchase APR applies, based on credit worthiness
• INTRO OFFER: Unlimited Cashback Match for all new cardmembers. Discover will automatically match all the cash back you’ve earned at the end of your first year! There’s no minimum spending or maximum rewards. You could turn $150 cash back into $300
• Earn 5% cash back on everyday purchases at different places you shop each quarter like grocery stores, restaurants, gas stations, and more, up to the quarterly maximum when you activate. Plus, earn unlimited 1% cash back on all other purchases
• Redeem cash back for any amount. No annual fee
• Terms and conditions apply

4.7

FinanceBuzz writers and editors score cards based on a number of objective features as well as our expert editorial assessment. Our partners do not influence how we rate products.

Apply Now

on Issuer's secure website

Rates and fees

Read Card Review

Intro Offer

INTRO OFFER: Unlimited Cashback Match for all new cardmembers. Discover will automatically match all the cash back you’ve earned at the end of your first year! There’s no minimum spending or maximum rewards. You could turn $150 cash back into $300

Annual Fee

$0

+ -

Why we like it

• The Discover it^® Cash Back is ideal for anyone who loves flexible rewards options.

• Cardholders can redeem their cash back for any amount.

• Earn 5% cash back on rotating bonus categories up to the quarterly maximum when you activate, along with 1% cash back on all purchases. Categories may include places like gas stations, grocery stores, restaurants, and more.

• Apply Now

---

Subscribe Today

Learn how to make an extra $200

Get vetted side hustles and proven ways to earn extra cash sent to your inbox.

or

Subscribe Now →

By submitting this form you agree to receive emails from FinanceBuzz and to the privacy policy and terms